Tatjana Odrljin, MD, PhD

VP Clinical Development

Tatjana Odrljin, Vice President of Clinical Development, has been leading Boston Pharmaceuticals’ NASH program since June 2021. Tanja has also lead several early programs since joining the company in October 2019 as a member of the R&D Leadership team. Tanja has diverse clinical development experience in number of therapeutic areas including vaccines, rare, metabolic, renal, and infectious diseases and was the key contributor or clinical lead for the development of several vaccines and drugs approved globally, including Menveo, Strensiq, LivtencityTM.   Tatjana worked for over 20 years in the Research and Development departments of Wyeth (now Pfizer), Novartis, Alexion, Shire, Takeda, and now Boston Pharmaceuticals. Prior to joining industry, Tanja worked as a research scientist in the fields of immunology/cell biology. She also held a full-time tenure track teaching position of immunology at University of Belgrade, School of Pharmacy before moving to the US. She holds MD and PhD degrees from University of Belgrade, former Yugoslavia, now Serbia.